November 2024 exceptional surveillance of suspected cancer: recognition and referral (NICE guideline NG12)
A tumour site review has been completed by Cancer Research UK (CRUK) in collaboration with the NHS National Cancer Programme. Its aim was to improve outcomes in tumour sites with higher rates of late-stage diagnosis. No suggestions were made in the tumour site review that impact the recommendations on suspected bladder cancer in this guideline.
Surveillance decision
We have found no new evidence that affects the recommendations on suspected bladder cancer.
This page was last updated: